Apr 30 2008
ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, unveiled today its DepoVax platform, a novel depot vaccine delivery system used to increase the efficacy and strength of vaccines. IVT has filed additional patents to protect the DepoVax concept.
"The results from our preclinical studies demonstrate that DepoVax is highly effective with a single dose," remarked Marc Mansour, vice president of research and development at IVT. "DepoVax is superior to conventional vaccine formulations in its ability to raise strong cellular and humoral immune responses to a variety of antigens, a hallmark of IVT's vaccine formulations."
DepoVax has been tested in pandemic influenza and therapeutic cancer models. The research shows DepoVax-vaccines deliver effective, long lasting results with only one dose.
DepoVax vaccines are readily amenable to commercialization. They can be manufactured in large batches, and are well suited for large scale distribution and long term storage. DepoVax vaccines are packaged and stored in a dry form, ensuring the stability of antigens which can otherwise be unstable in aqueous formulations. DepoVax vaccines are also easy to administer by health care practitioners, an important consideration for immunization programs targeting infectious diseases in a population.
"Our patented technology offers a dramatic boost to the effectiveness of existing vaccines," said Randal Chase, president and CEO of IVT. "An effective and easy-to-administer DepoVax vaccine would be a valuable tool for health authorities dealing with a pandemic and we are planning to take this into the clinic as soon as possible."
Research suggests no need for yellow fever vaccine booster after initial dose